Annual CCA Summit Is Now a Key Scientific Meeting in BTCs

December 2023, Vol 4, No 4
Milind M. Javle, MD
Hubert L. and Olive Stringer Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
M.D. Anderson Cancer Center
Houston, TX
Chair, NCI Task Force: Hepatobiliary Cancers

Dear Readers,

The 5th annual CCA Summit, held October 19-21, 2023, in Scottsdale, AZ, was a very successful meeting by all measures, and the summit has gradually become one of the key scientific meetings in biliary tract cancers (BTCs). This year’s summit was chaired by Flavio Rocha, MD, FACP, Oregon Health & Science University, Portland, OR, and the meeting presented key highlights in surgical, medical, and radiation oncology from the leaders in the field.

As always, the meeting included discussions of novel therapies, including targeted agents presented by Vaibhav Sahai, MBBS, MS, Midhun Malla, MD, MS, and Milind Javle, MD; antibody–drug conjugates by Renuka Iyer, MD; novel immunotherapies, including cell-based therapies, by Cassian Yee, MD; HER2/neu-directed therapies by Shubham Pant, MD, MBBS; and vaccines by Nilofer Azad, MD. These presentations set the theme for the meeting.

Multimodal therapies, which are critical for the successful management of cholangiocarcinoma (CCA), include radioembolization and stereotactic radiotherapy, and both are now being combined with immune checkpoint inhibitors. A key presentation on the surgical management of these tumors, provided by William Jarnagin, MD, FACS, was followed by an insightful session on the pros and cons of neoadjuvant therapy by Cristina Ferrone, MD, FACS. The surgeons participating in the summit highlighted that surgery is potentially curative; however, the addition of multimodal approaches augments the likelihood of long-term disease control.

The annual summit is increasingly focused on translational science, with important presentations on immunotherapy biomarkers by Greg Lesinski, PhD, MPH, and in vivo models by Rory Smoot, MD, and Larry Kwong, PhD.

In the concluding sessions, Bruce Lin, MD, and Kristen Spencer, DO, MPH, underscored the emerging role of biomarkers in CCA management. Novel radiologic methods for the management of locally advanced and surgically resectable CCA were discussed by Eugene Koay, MD, PhD, and Mike Choti, MD, MBA, FACS.

Finally, we all congratulate Paige Griffith, CRNP, for winning the CCA ONE Award as well as the other nominees, Kirsten Hernandez, BSN, RN, and Bobbie Khan, MS, RN, OCN, for their wonderful work.

Congratulations to all participants for a very successful summit. Mark your calendars for the next CCA Summit on October 17-19, 2024, in Lost Pines, TX!


Milind M. Javle, MD

Related Items

Advances in the Management of Patients With Biliary Cancer
By Milind M. Javle, MD
September 2023, Vol 4, No 3
As we approach the fall season, it is wonderful to reflect on some of the amazing research presented this year, most recently at the ASCO 2023 annual meeting. One of the major highlights of ASCO this year included the results of HER2/neu-directed novel therapies in biliary cancer. Shubham Pant, MD, MBBS, from MD Anderson Cancer Center, presented the results of the HERIZON-1 clinical trial of the bispecific antibody zanidatamab in HER2/neu-expressing biliary cancers.
Annual CCF Conference Brings Together All Stakeholders
By Milind M. Javle, MD
June 2023, Vol 4, No 2
This issue of CCA News highlights the Cholangiocarcinoma Foundation (CCF) 10th Annual Conference held in April. This meeting was chaired by Dr Chiara Branconi, a Lord Kelvin Adam Smith Reader at the University of Glasgow and a medical oncologist with Beatson Cancer Centre; and Dr Laura Goff, medical director of the Vanderbilt-Ingram Cancer Center’s Hematology and Oncology Division.
Exciting New Abstracts from the ASCO GI Cancers Symposium
By Milind M. Javle, MD
March 2023, Vol 4, No 1
Dr Javle provides his perspective on important abstracts presented at the ASCO Gastrointestinal Cancers Symposium, held January 19-21, 2023, in San Francisco, CA.
Highlights from the Fourth Annual CCA Summit
By Milind M. Javle, MD
December 2022, Vol 3, No 4
We have recently concluded the 4th Annual CCA Summit, which was held on October 13-15, 2022, in Denver, Colorado.
New Standard of Care Emerging for Treatment of BTCs
By Milind M. Javle, MD
September 2022, Vol 3, No 3
On September 2, 2022, the US Food and Drug Administration approved durvalumab in combination with gemcitabine/cisplatin for advanced biliary tract cancers (BTCs) on the basis of the TOPAZ-1 study.
Rapid Trajectory of Clinical Research in Biliary Tract Cancers
By Milind M. Javle, MD
March 2022, Vol 3, No 1
The 2022 ASCO GI Cancers Symposium clearly highlighted the rapid trajectory of clinical research in biliary tract cancers. One of the most eagerly anticipated studies, TOPAZ-1, was presented by Do-Youn Oh, MD, PhD, from Seoul National University Hospital in South Korea. This phase 3 clinical trial enrolled 685 patients and investigated the addition of the PD-L1–directed agent durvalu­mab to gemcitabine and cisplatin chemotherapy backbone versus these chemotherapies alone. The results demonstrated a statistically significant improvement in overall survival (OS), overall response rate (ORR), and progression-free survival (PFS), without dose-limiting toxicities.
Hot Topics at ASCO-GI 2022
By Milind M. Javle, MD
Dr Milind Javle provides his perspectives on key presentations on cholangiocarcinoma and biliary tract cancer at the 2022 ASCO Gastrointestinal Cancers Symposium.
Cholangiocarcinoma Research Continues to Thrive
By Milind M. Javle, MD
December 2021, Vol 2, No 4
The Third CCA Summit was held on October 21-22, 2021 in New Orleans. For the majority of the cholangiocarcinoma (CCA) community, this was their first “live” meeting since the pandemic.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: